Kevin Freeman Net Worth

The estimated Net Worth of Kevin D Freeman is at least $277 Tausend dollars as of 20 June 2024. Mr. Freeman owns over 2,500 units of Galectin Therapeutics Inc stock worth over $78,005 and over the last 12 years he sold GALT stock worth over $0. In addition, he makes $199,255 as Independent Director at Galectin Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Freeman GALT stock SEC Form 4 insiders trading

Kevin has made over 27 trades of the Galectin Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of GALT stock worth $5,950 on 20 June 2024.

The largest trade he's ever made was buying 10,000 units of Galectin Therapeutics Inc stock on 28 October 2022 worth over $14,100. On average, Kevin trades about 2,603 units every 106 days since 2013. As of 20 June 2024 he still owns at least 28,469 units of Galectin Therapeutics Inc stock.

You can see the complete history of Mr. Freeman stock trades at the bottom of the page.

Kevin Freeman biography

Kevin D. Freeman serves as Independent Director of the Company. Kevin D. Freeman, a director since May 2011, holds the Chartered Financial Analyst designation and is Chief Executive Officer of Cross Consulting and Services, LLC, an investment advisory and consulting firm founded in 2004. He is also author of a New York Times best-selling book about the stock market and economy and the host of a television program (Economic War Room with Kevin Freeman) that airs on BlazeTV. Formerly he was Chairman of Separate Account Solutions, Inc. and held several offices at Franklin Templeton Investment Services from 1991 to 2000. He holds a B.S. in business administration from University of Tulsa, Tulsa, Oklahoma.

What is the salary of Kevin Freeman?

As the Independent Director of Galectin Therapeutics Inc, the total compensation of Kevin Freeman at Galectin Therapeutics Inc is $199,255. There are 5 executives at Galectin Therapeutics Inc getting paid more, with Harold Shlevin having the highest compensation of $1,306,510.

How old is Kevin Freeman?

Kevin Freeman is 59, he's been the Independent Director of Galectin Therapeutics Inc since 2011. There are 10 older and 9 younger executives at Galectin Therapeutics Inc. The oldest executive at Galectin Therapeutics Inc is Gilbert Omenn, 79, who is the Independent Director.

What's Kevin Freeman's mailing address?

Kevin's mailing address filed with the SEC is C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS, GA, 30071.

Insiders trading at Galectin Therapeutics Inc

Over the last 14 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr und Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.

What does Galectin Therapeutics Inc do?

galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much

Complete history of Mr. Freeman stock trades at Galectin Therapeutics Inc

Galectin Therapeutics Inc executives and stock owners

Galectin Therapeutics Inc executives and other stock owners filed with the SEC include:

• Harold Shlevin,
  Director
• Jack Callicutt,
  Chief Financial Officer, Secretary
• Dr. Pol F. Boudes M.D., Ph.D.,
  Chief Medical Officer
• Dr. Pol F. Boudes,
  Chief Medical Officer
• Joel Lewis,
  Pres, CEO & Director
• Kevin Freeman,
  Independent Director
• Joel Lewis,
  President, Chief Executive Officer, Director
• Richard Uihlein,
  Independent Chairman of the Board
• Gilbert Amelio,
  Independent Director
• Gilbert Omenn,
  Independent Director
• Kary Eldred,
  Independent Director
• Eliezer Zomer,
  Executive Vice President - Manufacturing and Product Development
• Marc Rubin,
  Independent Director
• James Czirr,
  Director
• Richard Zordani,
  Independent Director
• Elissa Schwartz,
  Independent Director
• Pol Boudes,
  Chief Medical Officer
• J. Rex Horton,
  Executive Director - Regulatory Affairs and Quality Assurance
• Adam Allgood,
  Executive Director of Clinical Development
• Beth Knowles,
  Exec. Assistant & Officer Mang.
• Robert Tritt,
  Gen. Counsel
• Jack W. Callicutt CPA, CPA,
  CFO, Treasurer & Sec.
• Theodore Daniel Zucconi,
  Director
• John F Mauldin,
  Director
• Fund, L.P.10 X Capital Mana...,
  
• Steven Prelack,
  Director
• Arthur Greenberg,
  Director
• Khurram Jamil,
  Chief Medical Officer
• Benjamin Sr Carson,
  
• Stephen Shulman,
  Director
• Fund, L.P.10 X Capital Mana...,
  
• Peter G Traber,
  CEO and President
• Herman Paul Pressler,
  Director
• Thomas Mcgauley,
  Chief Financial Officer
• Rod D Martin,
  Director
• Jerald K Rome,
  Director
• Fund, L.P.Czirr James C10 X...,